Latebreakers: Keppra gets another epilepsy indication
Patients six years of age and older with primary generalized tonic-clonic seizures can now use levetiracetam (Keppra, UCB) as an adjunctive therapy to treat their epilepsy.
Patients six years of age and older with primary generalized tonic-clonic seizures can now use levetiracetam (Keppra, UCB) as an adjunctive therapy to treat their epilepsy. According to the manufacturer, levetiracetam is now approved to treat 80% of all seizure types, including partial-onset seizures in patients four years of age and older and myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. The IV formulation is approved for partial seizures as an alternative for adult patients when oral administration is temporarily not possible.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
